Association Between the 21-Gene Recurrence Score Assay and Risk of Locoregional Recurrence in Node-Negative, Estrogen Receptor–Positive Breast Cancer: Results From NSABP B-14 and NSABP B-20

Lignende værker

• Comparison of the Prognostic and Predictive Utilities of the 21-Gene Recurrence Score Assay and Adjuvant! for Women with Node-Negative, ER-Positive Breast Cancer: Results from NSABP B-14 and NSABP B-20
  af: Tang, Gong, et al.
  Udgivet: (2011)
• Prognostic Impact of the Combination of Recurrence Score and Quantitative Estrogen Receptor Expression (ESR1) on Predicting Late Distant Recurrence Risk in Estrogen Receptor–Positive Breast Cancer After 5 Years of Tamoxifen: Results From NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-28 and B-14
  af: Wolmark, Norman, et al.
  Udgivet: (2016)
• Adjuvant Tamoxifen Reduces Subsequent Breast Cancer in Women With Estrogen Receptor–Positive Ductal Carcinoma in Situ: A Study Based on NSABP Protocol B-24
  af: Allred, D. Craig, et al.
  Udgivet: (2012)
• 21-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer Treated With Chemo-Endocrine Therapy
  af: Mamounas, Eleftherios P., et al.
  Udgivet: (2017)
• Prognosis After Ipsilateral Breast Tumor Recurrence and Locoregional Recurrences in Patients Treated by Breast-Conserving Therapy in Five National Surgical Adjuvant Breast and Bowel Project Protocols of Node-Negative Breast Cancer
  af: Anderson, Stewart J., et al.
  Udgivet: (2009)